Press release, Helsinki, 14 October 2025 at 9 AM (EEST)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 therapy system from a new customer in Finland. The customer is a private healthcare provider that is acquiring their first Nexstim system.
The NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain in the EU. Earlier in October, the Nexstim received MDR (Regulation (EU) 2017/745) certification for the NBS 6 for the pre-procedural mapping of the speech and motor cortices of the brain. The NBS 6 enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.
Mikko Karvinen, CEO of Nexstim, comments: “We have an extensive customer base in Finland and are happy to strengthen our presence in the market with this order from a private healthcare provider. Today, nTMS mappings and therapy are available to more people in Finland than ever before and we will keep up the hard work to ensure high quality products and services to current and future customers.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com